ライフサイエンスコーパス: activating factor

1 in (SM) to ceramide and inactivates platelet activating factor.

2 a ribosomal protein functioning as an ATPase-activating factor.

3 s, which are possible precursors of platelet activating factor.

4 ls, and the mediators histamine and platelet-activating factor.

5 ole blood and dampened responses to platelet-activating factor.

6 g of this response by TNF-alpha and platelet-activating factor.

7 d by administration of histamine or platelet-activating factor.

8 ted with liver inflammation and serum B cell-activating factor.

9 as also reversed by the addition of platelet-activating factor.

10 elevated levels of pro-inflammatory platelet-activating factors.

11 aling and biological actions of specific RTK-activating factors.

12 induction of mesoendodermal fates by Smad2/3-activating factors.

13 een ezrin and F-actin as a function of these activating factors.

14 The apoptotic protease-activating factor 1 (Apaf-1) controls the onset of many

15 ding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C varepsilo

16 is, including apoptosome apoptotic peptidase activating factor 1 (APAF-1).

17 vage pathway dehydratase, apoptotic protease activating factor 1 (APAF1)-interacting protein (APIP),

18 associated with elevated apoptotic protease-activating factor 1 and a higher ratio of Bax/Bcl-2.

19 ng of the CARD of Apaf-1 (apoptotic protease activating factor 1), which consists of 97 amino acid re

20 , involving cytochrome c, apoptosis protease-activating factor-1 (Apaf-1), and caspase-9, or a caspas

21 or without shRNA against apoptotic protease-activating factor-1 (Apaf-1).

22 ssion or the depletion of apoptotic protease-activating factor-1 (Apaf-1).

23 ontrast to apoptosis, not apoptotic protease activating factor-1.

24 ury via activation of receptors for platelet-activating factor, a proinflammatory signaling molecule

25 tively truncated phospholipids, and platelet-activating factor, a remarkably potent and pleiotropic i

26 Low platelet activating factor acetyl hydrolase activity was associat

27 mor necrosis factor receptor I, and platelet activating factor acetyl hydrolase.

28 HDL-associated enzymes paraoxonase, platelet activating factor acetylhydrolase (PAF), and glutathione

29 We report that platelet-activating factor acetylhydrolase (PAFAH) Ib, comprised

30 e cytoplasmic PLA(2) enzyme complex platelet-activating factor acetylhydrolase (PAFAH) Ib, which cons

31 ilk containing diminished levels of platelet-activating factor acetylhydrolase (PAFAH).

32 Platelet-activating factor acetylhydrolase (PLA2G7) is a potent p

33 Platelet-activating factor acetylhydrolase 1B1 (LIS1), a critical

34 ), and antioxidant enzyme activity (platelet-activating factor acetylhydrolase [PAF-AH] and superoxid

35 y, such as suggesting that baseline platelet-activating factor acetylhydrolase activity levels are re

36 most potent effect was observed for platelet activating factor acetylhydrolase alpha (Paf-AHalpha), a

37 utations in the human gene encoding platelet-activating factor acetylhydrolase IB subunit alpha (Pafa

38 this study was to determine whether platelet-activating factor acetylhydrolase Sse and streptolysin S

39 y enzymatic assays for SpeB and the platelet-activating factor acetylhydrolase Sse, and a new type of

40 ChE and a new extracellular form of platelet-activating factor acetylhydrolase, PAFAH1b2.

41 Lp-PLA2, also known as platelet-activating factor acetylhydrolase, rapidly cleaves oxidi

42 ation of ectopic lymphoid structures (B-cell activating factor and B cell-attracting chemokine 1).

43 activated and primed for survival via B-cell activating factor and B-cell receptor-associated pathway

44 phosphorylation, homodimerization into gamma-activating factor and heterotrimerization into ISGF-3, b

45 As platelet-activating factor and HPC share structural semblances an

46 systemic inflammation with increased B cell-activating factor and IFN levels and induction of an IFN

47 abrogation of tolerance, no increased B cell-activating factor and IFN, and no IFN signature.

48 l counts, B-cell subset distribution, B cell-activating factor and immunoglobulin levels, and autoant

49 Interestingly, the activation of gamma-activating factor and ISGF3 was impaired only at early t

50 ary glands and abnormal expression of B cell-activating factor and its receptors.

51 The emergence of B-cell-activating factor and its related family members as crit

52 laxis suggest an important role for platelet-activating factor and its relationship to the need for p

53 l cell line induced upregulation of platelet activating factor and the fibrotic marker TGF-beta.

54 well as B-cell survival factor BAFF (B-cell activating factor) and antiapoptotic molecule Bcl-2 leve

55 orating the molecular adjuvants BAFF (B cell activating factor) and APRIL (a proliferation-inducing l

56 ors for chemokines, PGs, histamine, platelet activating factor, and anaphylatoxin.

57 on, splenic plasma cells, circulating B cell activating factor, and intragraft transcripts for major

58 Lysophosphatidylcholine, lyso-platelet-activating factor, and several phospholipid fatty acids

59 However, clear mast cell-activating factors are not always apparent.

60 Activation of the type I interferon/B cell-activating factor axis in SS has recently attracted part

61 o wild type in response to IgM, CD40, B cell-activating factor/B lymphocyte stimulator, CpG, and LPS.

62 At 2 years from transplantation, the B-cell activating factor/B-cell ratio was significantly higher

63 RABV-based vaccine expressing murine B cell activating factor (BAFF) (rRABV-mBAFF).

64 and B cell tropic factors, including B cell-activating factor (BAFF) and a proliferation-inducing li

65 gG-PB differentiation is dependent on B cell-activating factor (BAFF) and IL-10, whereas IgA-PB diffe

66 B-cell-activating factor (BAFF) and its receptor BAFF-R are imp

67 The cytokine B cell activating factor (BAFF) and its receptor, BAFF receptor

68 receptor editing and increased serum B cell-activating factor (BAFF) concentrations.

69 y evaluated B-cell subpopulations and B-cell activating factor (BAFF) in 136 patients (46 BOS, 41 no

70 We measured serum B-cell activating factor (BAFF) in 46 cGVHD patients receiving

71 B cell activating factor (BAFF) is a crucial survival factor fo

72 B-cell activating factor (BAFF) is an important cytokine for B-

73 The B cell-activating factor (BAFF) is critical for B cell developm

74 th cGVHD have significantly increased B cell-activating factor (BAFF) levels and that their B cells a

75 nce of alloantibodies and high plasma B cell-activating factor (BAFF) levels in patients with cGVHD s

76 Sustained increase in B-cell-activating factor (BAFF) mRNA in the CNS and BAFF recept

77 result, mutant TWEAK associated with B-cell-activating factor (BAFF) protein and down-regulated the

78 -) B cells express elevated levels of B-cell-activating factor (BAFF) receptor (BAFF-R) and as a resu

79 dent survival signals provided by the B cell-activating factor (BAFF) receptor (BAFF-R).

80 , as well as a defect in BCR-mediated B-cell-activating factor (BAFF) receptor up-regulation and subs

81 n of signals received through BCR and B cell activating factor (BAFF) receptor.

82 oth the B cell receptor (BCR) and the B cell-activating factor (BAFF) receptor.

83 B cell activating factor (BAFF) signals through BAFF-R to promo

84 B-cell activating factor (BAFF) single nucleotide polymorphisms

85 B cell activating factor (BAFF) stimulation of the BAFF recepto

86 evated IgG autoantibody reactivity to B cell-activating factor (BAFF) was associated with SLE compare

87 d autoantibodies directed against the B cell-activating factor (BAFF) were associated with greater di

88 13B (B lymphocyte stimulator (BLyS), B cell activating factor (BAFF)) promotes primary B cell prolif

89 B-cell activating factor (BAFF), a member of the TNF family, is

90 cidin, interleukin 1 (IL-1), IL-4 and B cell-activating factor (BAFF), after IgD crosslinking.

91 gand (sRANKL), osteoprotegerin (OPG), B-cell activating factor (BAFF), and a proliferation-inducing l

92 roliferation-inducing ligand (APRIL), B-cell activating factor (BAFF), interleukin (IL)-6, and IL-8 i

93 IL (a proliferation-inducing ligand), B-cell activating factor (BAFF), tumor necrosis factor-alpha (T

94 encoding the cytokine and drug target B-cell activating factor (BAFF), was associated with multiple s

95 iferation-inducing ligand (APRIL) and B-cell-activating factor (BAFF), whereas removal of terminal si

96 eptor (BAFFR) expression and inhibits B-cell activating factor (BAFF)-induced B-cell survival in a ce

97 The B-cell-activating factor (BAFF)-receptor (BAFF-R) is restricted

98 mirroring deficiency of the cytokine B cell-activating factor (BAFF).

99 lator (BLyS), also referred to as the B-cell activating factor (BAFF).

100 proliferate to the prosurvival factor B cell activating factor (BAFF).

101 included Tnfsf13b, which encodes the B-cell activating factor (BAFF).

102 dysfunctions, and one of these is the B cell-activating factor (BAFF).

103 Elevated B-cell-activating factor (BAFF; TNFSF13B) levels have been foun

104 with mice transgenic (Tg) for CD257 (B-cell activating factor, BAFF) developed CD5(+) B-cell leukemi

105 luence Mvarphi phenotype by mediating B cell-activating factor belonging to the TNF family (BAFF) and

106 The effects of B cell-activating factor belonging to the TNF family (BAFF) on

107 ity, NF-kappaB activation through the B cell-activating factor belonging to the TNF family (BAFF) rec

108 released the B-cell survival factor, B-cell activating factor belonging to the TNF family (BAFF), su

109 rimposing genetic deficiency of BAFF (B cell-activating factor belonging to the TNF family) onto CD15

110 esistant to the survival factor BAFF (B cell-activating factor belonging to the TNF family).

111 B-cell activating factor belonging to the tumor necrosis factor

112 BAFF (B cell-activating factor belonging to the tumor necrosis factor

113 and be required for the release of the IGFR-activating factor, beta-arrestins were found to act down

114 sses some of the pertinent aspects of B-cell-activating factor biology and considers how recent advan

115 ed in B lymphocyte development, BAFF (B cell activating factor, BlyS, TALL-1, CD257, TNFSF13B) and AP

116 a et al. report that the release of platelet-activating factor by basophils stimulated with immunoglo

117 PAWP) fulfils the criteria set for an oocyte-activating factor by inducing oocyte activation and bein

118 ing is elicited by the delivery of an oocyte-activating factor by the sperm.

119 lobulins (IgG, IgA), cytokines with platelet activating factor, calcium ionophore, or phorbol myrista

120 We identified IL-18 as a TRAF6-activating factor capable of enhancing lymphopenia-induc

121 inophils to chemoattractants (FMLP, platelet-activating factor, CCL11, CCL5, CXCL8) with respect to d

122 from spontaneous apoptosis induced by B cell-activating factors CD40L, TNF-alpha, and fibronectin.

123 SHU1, and UAF30, a component of the upstream activating factor complex (UAF), which regulates rDNA tr

124 Total airway IgE correlated with B-cell activating factor concentrations.

125 Serum levels of B-cell activating factor correlate with laboratory indices of l

126 and depends on the presence of an additional activating factor (e.g. the dipeptide benzyloxycarbonyl-

127 r and activator of transcription 3 (survival activating factor enhancement [SAFE] pathway) in the are

128 perfusion injury salvage kinase and survivor activating factor enhancement pathways in the infarct bo

129 perfusion injury salvage kinase and survivor activating factor enhancement pathways were similarly up

130 perfusion injury salvage kinase and survivor activating factor enhancement pathways, improved systoli

131 perfusion injury salvage kinase and survivor activating factor enhancement pathways.

132 The HIF-inducible myeloid-activating factors erythropoietin, stem cell factor (SCF

133 ence relieved B cells of the need for B cell activating factor for survival.

134 and rendering B cells independent of B cell activating factor for survival.

135 ately consisted of potent chemotactic and/or activating factors for phagocytes, including interleukin

136 DA was purified as a SAR-activating factor from vascular sap of Arabidopsis thali

137 Although ILC2-activating factors have been identified, the mechanisms

138 show here that VirA's receiver domain is an activating factor if virG is expressed from its native p

139 kinases, whereas it is independent of B-cell activating factor, IFN, and Toll-like receptor signaling

140 together, our results define G-CSF as a CSC-activating factor in neuroblastoma, suggest a comprehens

141 t phospholipids and biosynthesis of platelet-activating factor in noninflammatory remodeling pathway.

142 By neutralizing B cell-activating factor in vivo, we found an arrest in periphe

143 hase kinase 3beta inhibitor, blocks platelet activating factor-induced activation of glycogen synthas

144 In ADSA lymphoblasts, platelet-activating factor-induced Ca(2+) mobilization was signif

145 manner, LXs significantly inhibited platelet-activating factor-induced increases in leukocyte-platele

146 fter B-cell receptor stimulation, and B-cell activating factor-induced nuclear factor kappaB2/p52 gen

147 Following platelet-activating factor-induced shock, MK886 increased surviva

148 okines (insulin-like growth factor-1, B-cell activating factor, interleukin-6, interleukin-10).

149 ncement factor, and CpG ODN, serving as a DC activating factor, into sponge-like macroporous cryogels

150 YY1 is thus the first autosomal activating factor involved in a fundamental and conserve

151 ET formation after stimulation with platelet activating factor, ionomycin, or phorbol 12-myristate 13

152 LRC4 (interleukin-converting enzyme protease-activating factor [IPAF]) responds to the cytosolic pres

153 As known IRES-trans-activating factors (ITAF) were unaffected by IL-6, we us

154 yme (FXIa) that contributes to hemostasis by activating factor IX.

155 CD21(low) B cells and a reduction in B cell-activating factor levels.

156 st double-stranded DNA, and increased B cell-activating factor levels.

157 uced despite slightly increased serum B cell-activating factor levels.

158 -related protein 1 (P < .001) and osteoclast-activating factor MIP-1alpha (P < .05) also were signifi

159 oledronic acid, anti-DKK-1 MoAb, anti-B-cell activating factor MoAb and bortezomib, Btk inhibitor) sh

160 esting that SOX30 is a novel transcriptional activating factor of p53.

161 unctions of the TNF family cytokines, B cell-activating factor of the TNF family (BAFF) and a prolife

162 Mice overexpressing B cell activating factor of the TNF family (BAFF) develop syste

163 gmentation in mitogenic responses and B cell-activating factor of the TNF family (BAFF) receptor expr

164 B cell activating factor of the TNF family (BAFF), also known a

165 APRIL and the closely related ligand, B-cell activating factor of the TNF family (BAFF), bind these l

166 The B-cell activating factor of the TNF family (BAFF), nucleic acid

167 o associated with increased levels of B cell-activating factor of the TNF family (BAFF; also known as

168 DC-produced survival factors such as B cell-activating factor of the TNF family and a proliferation-

169 The B cell-activating factor of the TNF family receptor (BAFF-R), e

170 n are completely independent of BAFF (B cell-activating factor of the TNF family) or APRIL (a prolife

171 IgA production was enhanced by BAFF (B cell-activating factor of the TNF family), an innate mediator

172 The ASC survival factors B cell-activating factor of the tumor necrosis factor (TNF) fam

173 B cell activating factor of the tumor necrosis factor family (B

174 e effects of rituximab (anti-CD20) on B-cell-activating factor of the tumor necrosis factor family (B

175 B cell-activating factor of tumor necrosis factor family (BAFF)

176 Although many trans-activating factors of VEGF have been described, the tran

177 To analyze the influence of these activating factors on the organization of ezrin on lipid

178 tor of microglia) and fractalkine (microglia-activating factor) on visceral hyperalgesia in rats with

179 contribute to gene regulation by recruiting activating factors or remodelling nucleosomes.

180 emoattractants, such as chemokines, platelet-activating factor, or FMLP, through a process known as p

181 Platelet-activating factor (PAF [1-O-alkyl-2-acetyl-sn-glycero-3-

182 The platelet activating factor (PAF) acetyl hydrolase 1b (Pafah1b) co

183 The plasma form of platelet-activating factor (PAF) acetylhydrolase (PAF-AH), also k

184 Human plasma platelet-activating factor (PAF) acetylhydrolase functions by red

185 The platelet-activating factor (PAF) acetylhydrolase SsE produced by

186 1B2 and PAFAH1B3 subunits of type I platelet-activating factor (PAF) acetylhydrolase, a phospholipase

187 UV-induced keratinocyte-derived platelet-activating factor (PAF) activates mast cell migration, i

188 ycerophosphocholines (Ox-GPCs) with platelet-activating factor (PAF) activity produced non-enzymatica

189 chained phospholipids--inflammatory platelet-activating factor (PAF) and apoptotic oxidatively trunca

190 e hydrolytic inactivation of plasma platelet activating factor (PAF) and is also known as PAF acetylh

191 Platelet activating factor (PAF) and PAF-like lipids induce infla

192 nd photoimmune suppression, such as platelet-activating factor (PAF) and serotonin (5-HT) receptor an

193 ver the past few years, the role of platelet-activating factor (PAF) as a potent mediator involved in

194 We used platelet-activating factor (PAF) as a proinflammatory agonist.

195 s resveratrol and quercetin, on the platelet activating factor (PAF) biosynthetic enzymes, acetyl-CoA

196 Platelet-activating factor (PAF) causes wheal and flare responses

197 tte smoking leads to an increase in platelet-activating factor (PAF) content and PAF receptor express

198 ate surfactant protein-A (SP-A) and platelet-activating factor (PAF) expression, which increases in t

199 have implicated the lipid mediator platelet-activating factor (PAF) in UVB-mediated systemic immunos

200 f LE that the phospholipid mediator platelet-activating factor (PAF) increases in LE and that PAF rec

201 Platelet-activating factor (PAF) increases permeability to macrom

202 It is known that platelet-activating factor (PAF) induces severe endothelial barri

203 Platelet-activating factor (PAF) is a mediator of inflammation sh

204 Platelet-activating factor (PAF) is a naturally occurring phospho

205 Platelet-activating factor (PAF) is a phospholipid mediator with

206 Platelet-activating factor (PAF) is a potent lipid mediator that

207 Platelet-activating factor (PAF) is a potent phospholipid-derived

208 Platelet-activating factor (PAF) is a potent, bioactive phospholi

209 Platelet-activating factor (PAF) is a powerful proinflammatory me

210 Platelet-activating factor (PAF) is an important mediator and cor

211 The phospholipid platelet-activating factor (PAF) is an important mediator of infl

212 Platelet-activating factor (PAF) mediates an array of biological

213 Animal and human data show that platelet-activating factor (PAF) mediates the life-threatening ma

214 fter anaphylaxis, administration of platelet-activating factor (PAF) or histamine, and exposure to re

215 n-2 siRNA showed enhanced basal and platelet-activating factor (PAF) or lipopolysaccharide-stimulated

216 AA and PGE2 release, accompanied by platelet-activating factor (PAF) production.

217 LAU-0901, a novel platelet-activating factor (PAF) receptor antagonist, is highly n

218 hat antagonists of 5-HT(2A) and the platelet-activating factor (PAF) receptor can block cis-UCA-induc

219 llular Leishmania, we surmised that platelet-activating factor (PAF) receptor had a significant role

220 ssion are the binding of UV-induced platelet-activating factor (PAF) to its receptor and the binding

221 synonym KC) or the lipid mediator platetelet-activating factor (PAF) was only partially reduced.

222 proinflammatory glycerophospholipid platelet-activating factor (PAF) were markedly reduced in SRC-1/-

223 oiting molecular mimicry to degrade platelet-activating factor (PAF), a host-derived inflammatory pho

224 and BLP stimulated the synthesis of platelet activating factor (PAF), a potent lipid mediator, in hum

225 cytosis (CME), we hypothesized that platelet-activating factor (PAF), an effective chemoattractant th

226 ation generates the lipid mediator, platelet-activating factor (PAF), as well as oxidized phospholipi

227 with uridine 5'-diphosphate (UDP), platelet activating factor (PAF), or lysophosphatidic acid (LPA).

228 at the lipid inflammatory mediator, platelet-activating factor (PAF), synthesized by activated neutro

229 hibits hyperpermeability induced by platelet-activating factor (PAF), VEGF in ECV-CD8eNOSGFP (ECV-304

230 the lipid mediator of inflammation, platelet-activating factor (PAF).

231 neutrophil recruitment by targeting platelet-activating factor (PAF).

232 sophosphatidylcholine (lysoPCh) and platelet activating factor (PAF).

233 of prostaglandin I(2) (PGI(2)) and platelet-activating factor (PAF).

234 s, including adhesion molecules and platelet-activating factor (PAF).

235 ted, in part, by the lipid mediator platelet-activating factor (PAF).

236 ophil activation in the presence of platelet activating factor (PAF).

237 mong the proinflammatory mediators, platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-

238 e treated with fMLP with or without platelet-activating factor, PMA alone, or tumor necrosis factor a

239 gesting that cleavage of PABP and IRES trans-activating factors polypyrimidine tract-binding protein

240 G(+)); and (5) both TNFRSF17 mRNA and B cell-activating factor protein were up-regulated.

241 Signaling from the BCR and B cell activating factor receptor (BAFF-R or BR3) differentiall

242 sensitive to trophic factors, such as B cell-activating factor receptor (BAFF-R or BR3) during develo

243 was more dominantly controlled by the B-cell-activating factor receptor (BAFF-R), a gene that is link

244 that PTP1B negatively regulates CD40, B cell activating factor receptor (BAFF-R), and TLR4 signaling

245 Rather, high CD45 expression reduces B-cell activating factor receptor (BAFFR) expression and inhibi

246 ty to generate oxidized lipids with platelet-activating factor receptor (PAF-R) agonist activity.

247 ting oxidized lipid agonists of the platelet-activating factor receptor (PAF-R).

248 anoma metastasis, via activation of platelet-activating factor receptor (PAFR) and cAMP-responsive el

249 was blocked using a monoclonal anti-platelet activating factor receptor (PafR) antibody and Ginkgolid

250 We have previously shown that the Platelet-Activating Factor Receptor (PAFR) engagement in murine m

251 identified a prominent role for the platelet-activating factor receptor (PAFr) in hypoxia-associated

252 Platelet-activating factor receptor (PAFR) is a G protein-coupled

253 c activity in a manner dependent on platelet-activating factor receptor (PAFR) signaling.

254 immunoglobulin receptor (pIgR) and platelet-activating factor receptor (PAFr) to attach and invade c

255 n interleukin 1alpha (IL-1alpha) or platelet-activating factor receptor (PAFR), an important host rec

256 umannii binds to A549 cells through platelet-activating factor receptor (PAFR), resulting in activati

257 Moreover, expression of platelet-activating factor receptor (PAFR), which is known to pot

258 n immune responses include CD36 and platelet-activating factor receptor (PAFR).

259 cells is mediated by host-expressed platelet-activating factor receptor (PAFR).

260 cooperative signaling through BCR and B cell-activating factor receptor 3 (BR3).

261 ceptors and excluded key candidates platelet-activating factor receptor and CCR5.

262 ts revealed that L5 signals through platelet-activating factor receptor and lectin-like oxidized LDL

263 Platelet-activating factor receptor blockade protected synapses i

264 uction, proliferation of T cells, and B cell-activating factor receptor expression on B cells.

265 ect resulted in part from decreased platelet-activating factor receptor expression on endothelia and

266 or therapeutic agents that modulate platelet-activating factor receptor expression, may confer protec

267 Anaphylaxis was inhibited by platelet-activating factor receptor or histamine receptor 1 block

268 olvement for an unrelated GPCR (the platelet-activating factor receptor), indicating that it may be a

269 2, we show evidence for enhanced BCR, B cell-activating factor receptor, and CD40 coreceptor programs

270 r-1, protease activated receptor-3, platelet activating factor receptor, and factor V.

271 of B-cell activation molecules CD69, B-cell-activating factor receptor, and transmembrane activator

272 d IL-15 production in B cells through B cell-activating factor receptor, whereas IL-15, a potent grow

273 nctional itBreg cells in a CD40L- and B cell-activating factor receptor-dependent manner.

274 tor, or cell wall phosphorylcholine/platelet-activating factor receptor.

275 sidues on pneumococcal cell wall to platelet-activating factor receptor.

276 proteins suggests roles in recruiting and/or activating factors required to fill such gaps.

277 High-level soluble B-cell activating factor (sBAFF) was observed in kidney recipie

278 firing rate is directly determined by trans-activating factor search times.

279 onducted a biochemical screen for macrophage-activating factors secreted by metastatic carcinomas.

280 ound that histamine, serotonin, and platelet-activating factor, small molecule vascular permeabilizin

281 ophage, and neutrophil secretion of platelet-activating factor subsequent to FcgammaR stimulation by

282 ytokine production in response to macrophage-activating factors such as TLR ligands, instead broadly

283 expression of the autoregulatory viral trans-activating factor Tat is reduced to subthreshold levels.

284 The recruited neutrophils secreted a B cell-activating factor that highly accelerated plasma cell ge

285 letion of basophils and blockade of platelet-activating factor, the key components of the IgG1 pathwa

286 The approval of anti-B cell activating factor therapy and an increasing body of open

287 s responded to AgR stimulation and to B cell activating factor, they displayed decreased survival and

288 r, memory CD8(+) T cells that release the DC-activating factor TNF-alpha before the release of cytoto

289 ansferase activity of YopJ and identify this activating factor to be inositol hexakisphosphate (IP(6)

290 re used together with cytoplasmic Ran GTPase-activating factors to demonstrate that importin-alpha/CA

291 ediators, matrix metalloproteinase-9, B-cell activating factor, transforming growth factor-beta1, and

292 Upstream activating factor (UAF) is a multisubunit complex that f

293 or normal B cells with CD40-ligand or B-cell-activating factor upregulated miR-155 and enhanced sensi

294 ines (CXCL13, CCL19, CCL21, CCL1, and B-cell-activating factor) was increased in pancreatic and serum

295 Lysophosphatidylcholine and lyso-platelet-activating factor were also associated directly with ins

296 Most of the complement-activating factors were upregulated, whereas the complem

297 tryptamine), platelet factor 4, and platelet-activating factor, which specifically stimulated differe

298 PAR-1 and its activating factors, which are expressed on tumor cells a

299 The venom is now known to act by directly activating factor X, and a form of the clotting test is

300 actor/selenocysteine tRNA gene transcription activating factor/zinc finger protein 143 (SBF/Staf/ZNF1